Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. Our lead program is expected to enter the clinic in early 2021.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/10/20 | $80,000,000 | Series B |
Fidelity Management & Research Company GV  Mithril Capital Management Omega Funds OrbiMed Advisors Polaris Partners Population Health Partners | undisclosed |
| 04/20/21 | $336,000,000 | Series C |
ArrowMark Partners Federated Hermes Fidelity Management & Research Company Foresite Capital GV Mithril Capital Management OrbiMed Advisors Polaris Partners Population Health Partners PremjiInvest RA Capital Management Redmile Group | undisclosed |
